Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 31.00 | |
10 mg | In stock | $ 50.00 | |
25 mg | In stock | $ 100.00 | |
50 mg | In stock | $ 177.00 | |
100 mg | In stock | $ 297.00 | |
200 mg | In stock | $ 443.00 | |
500 mg | In stock | $ 718.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 34.00 |
Description | Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis. |
Targets&IC50 | Abl (E255K):0.53 μM, Abl:0.21 μM, Abl (T315I):0.64 μM |
In vitro | In the COLO205 tumor xenograft model, the synergistic use of Nocodazole with Ketoconazole enhances apoptosis induction and exerts a stronger inhibitory effect on tumor volume and weight in mice. |
In vivo | Nocodazole demonstrates high affinity for oncogenic kinases, such as phosphorylated ABL (Kd: 0.091 μM), c-KIT (Kd: 1.6 μM), BRAF (Kd: 1.8 μM), and MEK (Kd: 1.6 μM). It also exhibits significant affinity towards ABL(E255K) phosphorylation (Kd: 0.12 μM), ABL(T315I) phosphorylation (Kd: 0.17 μM), BRAF(V600E) (Kd: 1.1 μM), and PI3Kγ (Kd: 1.5 μM). At high concentrations, Nocodazole can rapidly depolymerize microtubules in cells, whereas at lower concentrations, it inhibits the dynamic instability of microtubules. Treatment with Nocodazole for 6 hours to synchronize cells in the mitotic phase, followed by the addition of varying concentrations of Taxol, results in G1 phase arrest (IC50: 4 nM). |
Cell Research | Nocodazole is dissolved in a final concentration of 0.05% DMSO. Proteins are loaded at 50 μg/lane and separated by 12% (w:v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted, and probed with antibodies for cyclin E, p53, p21/CIP1, p27/KIP1, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), cyclin A, cyclin D1, cyclin D3, cyclin B, CDK2, CDK4, and cytochrome C. Immunoreactive bands are visualized by incubating with the colorigenic substrates nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate. The expression of GAPDH is used as the control for equal protein loading. |
Synonyms | R17934, Oncodazole |
Molecular Weight | 301.32 |
Formula | C14H11N3O3S |
CAS No. | 31430-18-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 12.5 mg/mL (41.48 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Nocodazole 31430-18-9 Angiogenesis Apoptosis Autophagy Cytoskeletal Signaling DNA Damage/DNA Repair Tyrosine Kinase/Adaptors Microtubule Associated Bcr-Abl CRISPR/Cas9 Inhibitor R17934 Microtubule/Tubulin Oncodazole inhibit R 17934 R-17934 inhibitor